<DOC>
	<DOCNO>NCT00967590</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled study evaluate efficacy , safety tolerability RO5036505 patient inadequately control moderate severe asthma . Patients randomize receive either RO5036505 ( 380mg iv infusion weekly ) placebo 8 week . Patients standardize inhaled corticosteroid/long-acting beta-agonist regimen study treatment . Target sample size 50-100 individual .</brief_summary>
	<brief_title>A Study RO5036505 Patients With Moderate Severe Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>adult patient , 1870 year age moderate severe asthma &gt; /=2 year ACQ score &gt; /= 1.5 ICS LABA regimen moderate high dose nonsmoker oral corticosteroid use within 4 week prior screen current escalate immunotherapy acute infection/antibiotic therapy within 4 week prior screen , chronic infection pulmonary disease asthma therapy approve monoclonal antibody biologic agent within 12 month prior screen previous exposure investigational monoclonal antibody biologics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>